Published in Nat Genet on June 22, 2014
ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol (2015) 3.22
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet (2016) 2.28
Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet (2015) 2.10
Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet (2015) 1.89
Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov (2015) 1.76
Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. PLoS Med (2015) 1.74
Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. Gastroenterology (2016) 1.52
Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun (2014) 1.42
Deregulation of the FOXM1 target gene network and its coregulatory partners in oesophageal adenocarcinoma. Mol Cancer (2015) 1.41
Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma. J Pathol (2015) 1.06
Precision prevention of oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol (2015) 0.88
Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nat Rev Cancer (2016) 0.87
Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus. Cancer Prev Res (Phila) (2015) 0.87
Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma. Mol Cell Proteomics (2015) 0.85
Mobile element insertions are frequent in oesophageal adenocarcinomas and can mislead paired-end sequencing analysis. BMC Genomics (2015) 0.84
Somatic mosaicism: on the road to cancer. Nat Rev Cancer (2015) 0.83
Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. Br J Cancer (2015) 0.81
Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology (2015) 0.81
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. Br J Cancer (2015) 0.81
Crambled: A Shiny application to enable intuitive resolution of conflicting cellularity estimates. F1000Res (2015) 0.79
From genomics to diagnostics of esophageal adenocarcinoma. Nat Genet (2014) 0.79
Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis. Dig Dis Sci (2015) 0.79
Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study. Gut (2015) 0.78
Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am (2015) 0.78
Evolution of oesophageal adenocarcinoma from metaplastic columnar epithelium without goblet cells in Barrett's oesophagus. Gut (2015) 0.78
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat Commun (2016) 0.78
Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective. Cell Mol Gastroenterol Hepatol (2017) 0.77
Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus. Nat Commun (2016) 0.77
Surgery in the era of the 'omics revolution. Br J Surg (2015) 0.77
Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinoma. Oncotarget (2015) 0.77
Whole-genome sequencing of nine esophageal adenocarcinoma cell lines. F1000Res (2016) 0.76
A population genetics perspective on the determinants of intra-tumor heterogeneity. Biochim Biophys Acta (2017) 0.76
Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. Carcinogenesis (2016) 0.76
Early-Stage Induction of SWI/SNF Mutations during Esophageal Squamous Cell Carcinogenesis. PLoS One (2016) 0.76
HES5 silencing is an early and recurrent change in prostate tumourigenesis. Endocr Relat Cancer (2015) 0.76
Barrett's oesophagus: frequency and prediction of dysplasia and cancer. Best Pract Res Clin Gastroenterol (2015) 0.76
A comparative analysis of whole genome sequencing of oesophageal adenocarcinoma pre- and post-chemotherapy. Genome Res (2017) 0.76
Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma. Br J Cancer (2016) 0.75
Columnar Metaplasia in Three Types of Surgical Mouse Models of Esophageal Reflux. Cell Mol Gastroenterol Hepatol (2017) 0.75
Epigenetic reduction of DNA repair in progression to gastrointestinal cancer. World J Gastrointest Oncol (2015) 0.75
Etiology and Prevention of Esophageal Cancer. Gastrointest Tumors (2016) 0.75
Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis. Cancers (Basel) (2015) 0.75
Limitations of the Driver/Passenger Model in Cancer Prevention. Cancer Prev Res (Phila) (2016) 0.75
Clonal evolution of colorectal cancer in IBD. Nat Rev Gastroenterol Hepatol (2017) 0.75
Genetics: Driver genes are mutated early in the course of oesophageal adenocarcinoma. Nat Rev Clin Oncol (2014) 0.75
Combining simple patient-oriented tests with state-of-the-art molecular diagnostics for early diagnosis of cancer. United European Gastroenterol J (2015) 0.75
Genetics. Driver genes are mutated early in the course of oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol (2014) 0.75
Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics (2017) 0.75
Emerging therapeutic targets in esophageal adenocarcinoma. Oncotarget (2016) 0.75
Base changes in tumour DNA have the power to reveal the causes and evolution of cancer. Oncogene (2016) 0.75
Surrogate Markers: Lessons from the Next Gen? Cancer Prev Res (Phila) (2016) 0.75
Methylated B3GAT2 and ZNF793 Are Potential Detection Biomarkers for Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev (2015) 0.75
Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2017) 0.75
Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples. BMC Res Notes (2017) 0.75
Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. Sci Rep (2016) 0.75
Cooperative genomic alteration network reveals molecular classification across 12 major cancer types. Nucleic Acids Res (2016) 0.75
Integrated molecular analysis reveals complex interactions between genomic and epigenomic alterations in esophageal adenocarcinomas. Sci Rep (2017) 0.75
Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution. Medicines (Basel) (2017) 0.75
Increased IFRD1 Expression in Human Colon Cancers Predicts Reduced Patient Survival. Dig Dis Sci (2017) 0.75
From Heartburn to Barrett's Esophagus, and Beyond. World J Surg (2017) 0.75
Intratumoral heterogeneity of esophageal squamous cell carcinoma. J Thorac Dis (2017) 0.75
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
The clonal evolution of tumor cell populations. Science (1976) 24.39
VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics (2009) 15.08
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Clonal evolution in cancer. Nature (2012) 11.07
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
The life history of 21 breast cancers. Cell (2012) 10.59
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet (2006) 6.71
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet (2011) 5.67
SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics (2011) 5.62
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology (2013) 4.43
Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst (2011) 4.31
Cancer genomics: from discovery science to personalized medicine. Nat Med (2011) 3.66
Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ (2010) 3.44
Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med (2013) 2.58
Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov (2012) 2.39
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26
Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell (2012) 2.16
Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol (2010) 1.90
Molecular identification of latent precancers in histologically normal endometrium. Cancer Res (2001) 1.84
Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut (2009) 1.48
Breaking a vicious cycle. Sci Transl Med (2013) 1.36
Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene (2013) 1.33
Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc (2002) 1.09
Garlic, silver bullets, and surveillance upper endoscopy for Barrett's esophagus. Gastroenterology (2013) 0.97
Identification and clinical implementation of biomarkers for Barrett's esophagus. Gastroenterology (2012) 0.92
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Low-coverage single-cell mRNA sequencing reveals cellular heterogeneity and activated signaling pathways in developing cerebral cortex. Nat Biotechnol (2014) 3.43
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet (2016) 2.28
Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet (2015) 1.89
Autofluorescence-Directed Confocal Endomicroscopy in Combination With a Three-Biomarker Panel Can Inform Management Decisions in Barrett's Esophagus. Am J Gastroenterol (2015) 0.79
Whole-genome sequencing of nine esophageal adenocarcinoma cell lines. F1000Res (2016) 0.76
Decision making, quality of life and prophylactic gastrectomy in carriers of pathogenic CDH1 mutations. Transl Gastroenterol Hepatol (2017) 0.75
Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. Sci Rep (2016) 0.75
Open chromatin profiling identifies AP1 as a transcriptional regulator in oesophageal adenocarcinoma. PLoS Genet (2017) 0.75
Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol (2016) 0.75
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. Br J Surg (2017) 0.75
Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. Gut (2017) 0.75